Technical analysis of Curis, Inc. (CRIS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Price Performance
| 1 month | -34.12% |
| 3 months | -86.70% |
| Year-to-date | -94.33% |
| 1 year | -96.65% |
| 3 years | -99.40% |
| 5 years | -99.97% |
52-Week Range
| 52-week High | $35.80 |
| 52-week Low | $1.07 |
| Avg Volume (90d) | 215K |
Technical Indicators
| SMA 50 | $3.04 |
| SMA 200 | $12.47 |
| Beta | 3.14 |
| 30-day Volatility (annualised) | 159.9% |
| Price vs SMA 50 | -63.2% |
| Price vs SMA 200 | -91.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $29.80 | |
| 2025-11 | $27.40 | -8.1% |
| 2025-12 | $19.74 | -28.0% |
| 2026-01 | $17.96 | -9.0% |
| 2026-02 | $22.80 | +26.9% |
| 2026-03 | $10.95 | -52.0% |
| 2026-04 | $12.00 | +9.6% |
| 2026-05 | $11.34 | -5.5% |
| 2026-06 | $10.44 | -7.9% |
| 2026-07 | $5.02 | -51.9% |
| 2026-08 | $1.49 | -70.3% |
| 2026-09 | $1.12 | -24.8% |
Price
| Price | $1.12 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | 0.09 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.22 |
| Current Ratio | 0.49 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -92.32 |